肿瘤基因单核苷酸多态性研究及个体化医疗的思考
许玲,孙大志, 余志红, 中国人民解放军第二军医大学附属长征医院中医科 上海市200003
许玲, 女,1967-3-8出生,浙江衢州人,汉族.1995年毕业于上海中医药大学,获博士学位,副教授,主要从事中西医结合防治肿瘤的临床研究.
国家自然基金资助项目,No. 30271626
项目负责人: 许玲,200003, 上海市凤阳路415号,中国人民解放军第二军医大学长征医院中医科. czzyk@smmu.edu.cn
电话:021-63610109-73406
, http://www.100md.com
收稿日期:2005-01-10 接受日期:2005-01-20
摘要
单核苷酸多态性(SNPs)是指存在于某一人群或个体基因组内的单个碱基发生突变，从而导致了群体与群体及个体与个体之间的差异.肿瘤患者个体治疗敏感性和与治疗相关的毒副反应等均与SNPs有关.解析人类基因组的碱基序列差异，将为相关联的医药领域疾病的治疗带来革命性飞跃，在不久的将来有望实现“量体裁衣”式的个体化给药治疗方案.
关键词: 单核苷酸多态性;肿瘤;基因;个体化医疗
许玲,孙大志,余志红.肿瘤基因单核苷酸多态性研究及个体化医疗的思考.世界华人消化杂志 2005;13(5):592-5951 Taningher M, Malacarne D, Izzotti A, Ugolini D, Parodi S. Drug metabolism polymorphisms as modulators of
, 百拇医药
cancer susceptibility. Mutat Res 1999;436:227-261
2 Mohrenweiser HW, Jones IM. Variationin DNA repair is a factor in cancer susceptibility:a paradigm for thepromises
and perils of individual and populationrisk estimation? Mutat Res 1998;400:15-24
3 汉雨生, 王明荣. 单核苷酸多态性分析技术及其在肿瘤研究中的应用. 国外医学肿瘤学分册 2003;30:189-193
4 基因有限公司专家组. 单核苷酸多态性研究前沿及主要技术方法. 生物学教学 2004;29:3-4
, 百拇医药
5 Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately
up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996;49:311-318
6 Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NK, Lovett BD, Nowell PC, Blair IA, Rebbeck TR.
Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 1998;95:13176-13181
, 百拇医药
7 Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M,Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A
promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-391
8 杨兴升, 关根正幸, 仑田仁, 田中宪一. MRP2基因单核苷酸多态性对晚期卵巢癌铂类化疗敏感性的影响.
, http://www.100md.com
实用妇产科杂志 2004;20:153-155
9 王佐广, 温绍君, 吴兆苏. 临床药物应用与单核苷酸多态性. 中国医药导刊 2002;4:45-46
10 Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB,Schuetz JD, Schuetz EG, Wilkinson GR. Identification of functionally variant MDR1 alleles among european americans
and african americans. Clin Pharmacol Ther 2001;70:189-199
, http://www.100md.com
11 迟志宏, 刘端祺, 张积仁. CYP和MDRl的单核苷酸多态性对肿瘤化疗疗效的影响. 解放军医学杂志
2003;28:752-753
12 Ross D, Traver RD, Siegel D, Kuehl BL, Misra V, Rauth AM. A polymorphism in NAD(P)H: quinone oxidoreductase
(NQO1): relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity. Br J Cancer
1996;74:995-996
13 Lin P, Wang HJ, Lee H, Lee HS, Wang SL, Hsueh YM, Tsai KJ, Chen CY. NAD(P)H:quinone oxidoreductase
, 百拇医药
polymorphism and lung cancer in Taiwan. J Toxicol Environ Health A 1999;58:187-197
14 Kolesar JM, Pritchard SC, Kerr KM, Kim K, Nicolson MC, McLeod H. Evaluation of NQO1 gene expression and variant
allele in human NSCLC tumors and matched normal lung tissue. Int J Oncol 2002;21:1119-1124
编辑 张海宁, 百拇医药( 许 玲, 孙大志, 余志红)
许玲, 女,1967-3-8出生,浙江衢州人,汉族.1995年毕业于上海中医药大学,获博士学位,副教授,主要从事中西医结合防治肿瘤的临床研究.
国家自然基金资助项目,No. 30271626
项目负责人: 许玲,200003, 上海市凤阳路415号,中国人民解放军第二军医大学长征医院中医科. czzyk@smmu.edu.cn
电话:021-63610109-73406
, http://www.100md.com
收稿日期:2005-01-10 接受日期:2005-01-20
摘要
单核苷酸多态性(SNPs)是指存在于某一人群或个体基因组内的单个碱基发生突变，从而导致了群体与群体及个体与个体之间的差异.肿瘤患者个体治疗敏感性和与治疗相关的毒副反应等均与SNPs有关.解析人类基因组的碱基序列差异，将为相关联的医药领域疾病的治疗带来革命性飞跃，在不久的将来有望实现“量体裁衣”式的个体化给药治疗方案.
关键词: 单核苷酸多态性;肿瘤;基因;个体化医疗
许玲,孙大志,余志红.肿瘤基因单核苷酸多态性研究及个体化医疗的思考.世界华人消化杂志 2005;13(5):592-5951 Taningher M, Malacarne D, Izzotti A, Ugolini D, Parodi S. Drug metabolism polymorphisms as modulators of
, 百拇医药
cancer susceptibility. Mutat Res 1999;436:227-261
2 Mohrenweiser HW, Jones IM. Variationin DNA repair is a factor in cancer susceptibility:a paradigm for thepromises
and perils of individual and populationrisk estimation? Mutat Res 1998;400:15-24
3 汉雨生, 王明荣. 单核苷酸多态性分析技术及其在肿瘤研究中的应用. 国外医学肿瘤学分册 2003;30:189-193
4 基因有限公司专家组. 单核苷酸多态性研究前沿及主要技术方法. 生物学教学 2004;29:3-4
, 百拇医药
5 Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately
up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996;49:311-318
6 Felix CA, Walker AH, Lange BJ, Williams TM, Winick NJ, Cheung NK, Lovett BD, Nowell PC, Blair IA, Rebbeck TR.
Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA 1998;95:13176-13181
, 百拇医药
7 Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M,Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A
promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-391
8 杨兴升, 关根正幸, 仑田仁, 田中宪一. MRP2基因单核苷酸多态性对晚期卵巢癌铂类化疗敏感性的影响.
, http://www.100md.com
实用妇产科杂志 2004;20:153-155
9 王佐广, 温绍君, 吴兆苏. 临床药物应用与单核苷酸多态性. 中国医药导刊 2002;4:45-46
10 Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB,Schuetz JD, Schuetz EG, Wilkinson GR. Identification of functionally variant MDR1 alleles among european americans
and african americans. Clin Pharmacol Ther 2001;70:189-199
, http://www.100md.com
11 迟志宏, 刘端祺, 张积仁. CYP和MDRl的单核苷酸多态性对肿瘤化疗疗效的影响. 解放军医学杂志
2003;28:752-753
12 Ross D, Traver RD, Siegel D, Kuehl BL, Misra V, Rauth AM. A polymorphism in NAD(P)H: quinone oxidoreductase
(NQO1): relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity. Br J Cancer
1996;74:995-996
13 Lin P, Wang HJ, Lee H, Lee HS, Wang SL, Hsueh YM, Tsai KJ, Chen CY. NAD(P)H:quinone oxidoreductase
, 百拇医药
polymorphism and lung cancer in Taiwan. J Toxicol Environ Health A 1999;58:187-197
14 Kolesar JM, Pritchard SC, Kerr KM, Kim K, Nicolson MC, McLeod H. Evaluation of NQO1 gene expression and variant
allele in human NSCLC tumors and matched normal lung tissue. Int J Oncol 2002;21:1119-1124
编辑 张海宁, 百拇医药( 许 玲, 孙大志, 余志红)
